The EMA has issued Questions and Answers to Stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use.
The document is intended to give practical guidance on the applicable rules to centrally authorised medicinal products for human use intended to be placed on the market in Northern Ireland before and after the application of Regulation (EU) 2023/1182.
See here for ‘Questions and Answers’ document and here for ‘Legal Content’ link
Read More
Most risk assessments are completed, signed off and never looked at again. Everyone is happy. Or are they? On paper, this looks like compliance with ICH Q9(R1) Quality Risk Management Principles. In reality, it often misses the point entirely. Risk assessment is...
Under the EU framework, manufacturers holding an MIA are authorised to distribute medicinal products. While there is no explicit requirement to appoint an RP in the same way as a wholesale distributor, this does not remove their obligations to ensure distribution...
For the past thirty years, Europe has built one of the world's most respected medicine regulatory systems. The centralised authorisation process has enabled groundbreaking treatments to reach millions of patients while maintaining the rigorous standards of quality,...
Strategy
Sign up for our newsletter today and stay informed on the latest regulatory updates and industry insights.